Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.75 |
| ▸ | MAPT | P10636 | 6/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.75 |
| ▸ | HPGD | P15428 | 4/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21558830 | 0.84 | MAPT (0.66) | L3MBTL1MAPTTDP1HPGDALDH1A1 | |
| SCHEMBL11836462 | 0.83 | TDP1 (0.60) | L3MBTL1MAPTTDP1HPGDALDH1A1 | |
| SCHEMBL13178888 | 0.83 | MAPT (0.56) | L3MBTL1MAPTTDP1HPGDALDH1A1 | |
| SCHEMBL16834317 | 0.83 | L3MBTL1 (0.75) | L3MBTL1MAPTTDP1HPGDALDH1A1 | |
| SCHEMBL12603165 | 0.82 | L3MBTL1 (0.69) | L3MBTL1MAPTTDP1HPGDALDH1A1 | |
| SCHEMBL28446720 | 0.82 | CYP1A2 (0.57) | L3MBTL1MAPTTDP1HPGDALDH1A1 | |
| SCHEMBL1847263 | 0.81 | ALDH1A1 (0.58) | L3MBTL1MAPTTDP1HPGDALDH1A1 | |
| SCHEMBL805356 | 0.80 | MAPT (0.61) | L3MBTL1MAPTTDP1HPGDALDH1A1 | |
| SCHEMBL30423350 | 0.80 | L3MBTL1 (0.58) | L3MBTL1MAPTTDP1HPGDALDH1A1 | |
| SCHEMBL15667351 | 0.80 | TDP1 (0.66) | L3MBTL1MAPTTDP1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3865474-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2021-08-18 | — | — | EP | disclosed |
| US-20210238159-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2021-08-05 | — | — | US | disclosed |
| EP-3736270-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| EP-3736267-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-27 | — | — | US | disclosed |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-20 | — | — | US | disclosed |
| US-10844042-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-24 | — | — | US | disclosed |
| US-10844041-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-24 | — | — | US | disclosed |
| CN-111954664-A | Cystic fibrosis transmembrane conductance regulator and methods of use | 艾伯维海外有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3736267-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-11-11 | — | — | EP | disclosed |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-17 | — | — | US | disclosed |
| EP-1463501-B1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070099919-A1 | Composition and synthesis of new reagents for inhibition of HIV replication | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-03 | — | — | US | disclosed |
| US-7169761-B2 | Azulene derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1553094-A1 | AZULENE DERIVATIVES AND SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-20050124555-A1 | Azulene derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2005-06-09 | — | — | US | disclosed |
| EP-1463501-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-6617346-B1 | Inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity | HOFFMANN-LA ROCHE INC. | 2003-09-09 | — | — | US | disclosed |
| WO-2003051360-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238159-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | L3MBTL1 3452/4885MAPT 4885/4885TDP1 4790/4885 |
| US-20050124555-A1 | Azulene derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | L3MBTL1 3411/4885MAPT 4266/4885TDP1 4009/4885 |
| US-10844042-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | L3MBTL1 3452/4885MAPT 4885/4885TDP1 4790/4885 |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | L3MBTL1 3452/4885MAPT 4885/4885TDP1 4790/4885 |
| US-20070099919-A1 | Composition and synthesis of new reagents for inhibition of HIV replication | REV1, MAVS, ISG15 | L3MBTL1 1667/4885MAPT 2825/4885TDP1 1569/4885 |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | L3MBTL1 63/4885MAPT 4038/4885TDP1 835/4885 |
| US-10844041-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | L3MBTL1 3452/4885MAPT 4885/4885TDP1 4790/4885 |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | L3MBTL1 3452/4885MAPT 4885/4885TDP1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.